Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V (Open-House-Modell)
Description
The subject of this publication is the conclusion of agreements under Section 130a, Paragraph 8, SGB V for finished medicinal products with various active substances or active substance combinations within the framework of a so-called "Open-House Model". Admission or contract conclusion can take place at any time and under the same conditions. Individual contract negotiations will not be conducted. The earliest contract start date is 01.07.2025. Based on this, the contract duration is a maximum of 24 months. The contract ends on 30.06.2026, regardless of the contract start date. If AOK Hessen conducts a tender for exclusive contracts in the form of an open procedure for the active substances during the contract period, the contracts concluded under this publication will be terminated in accordance with the contractual provisions. The publication is cancelled with immediate effect. A new publication for this active substance has already appeared on 18.05.2026 (OH 108).
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Medical equipments, pharmaceuticals and personal care products – 1/DLII6/VM109 - RV Impfstoff Influenza
Bundesamt für Infrastruktur, Umweltschutz und Dienstleistungen der BundeswehrGermanyMedical equipments, pharmaceuticals and personal care productsPharmaceutical productsGeneral anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agentsDeadline in 14 daysPublished on Oct 18, 2026
Germany – Medical equipments, pharmaceuticals and personal care products – Blutentnahme
EK-UNICO GmbHGermanyMedical equipments, pharmaceuticals and personal care productsVenepuncture, blood sampling devicesDeadline in 29 daysPublished on Oct 18, 2026
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pankreatin (ATC-Code nach WHO: A09AA02)
AOK PLUS - Die Gesundheitskasse für Sachsen und ThüringenGermanyPharmaceutical productsDeadline in 42 daysPublished on Oct 18, 2026
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Golimumab (ATC-Code nach WHO: L04AB06)
AOK PLUS - Die Gesundheitskasse für Sachsen und ThüringenGermanyPharmaceutical productsDeadline in 620 daysPublished on Oct 18, 2026